ClinicalTrials.gg
CompletedNCT02052336Updated Dec 15, 2016

Drug-Drug Interaction Study Between CJ-12420 and Clarithromycin in Healthy Male Subjects

A Phase 1 interventional study of CJ-12420 200mg + Clarithromycin 500mg and CJ-12420 200mg in Healthy, sponsored by HK inno.N Corporation. Completed at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-12-15.

Sponsored by HK inno.N Corporation · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
19 Years to 45 Years
Sex
Male
01

Study summary

Primary Objective: To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.

Secondary Objective(s): To assess the safety of the coadministration of multiple dose of CJ-12420 and clarithromycin in healthy subjects

Read the detailed description

An open-label, randomized, 6-sequence, 3-period, 3-treatment crossover design

02

Conditions studied

  • Healthy

Keywords

  • Drug-Drug interaction
  • Pharmacokinetics
03

In context

Lead sponsor

HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male volunteers in the age between 19 and 45 years old
  • (BMI) in the range of 19 to 28 kg/m2
  • Understand the requirement of the study and voluntarily consent to paticipate in the study

Exclusion criteria

Exclusion Criteria:

  • History of medical history or disease (hepatic, kidney, gastrointestinal,respiratory, musculoskeletal, endocrine,neuro-psychiatric, haemato-oncologic,urinary tract, cardiac arrhythmia and cardiovascular system) judged by investigator.
  • Clinically significant abnormal laboratory results within at least 28 days prior to the first day of drug administration. or ALT > 1.25 times of upper limit value Total > 1.5 times of upper limit value estimated :less than 80 mL/min
  • Clinically significant abnormal results within at least 28 days prior to the first day of drug administration PR ≥ 210 msec QRS ≥ 120 msec ≥ 500 msec QTcF ≥ 500 msec
  • Clinically significant reaction against drug or other drugs
  • history of drug abuse or "positive" results from drug screening test.
  • Take medicine such as prescription medicine or herbal medicine, over-the-counter drug, vitamin supplements
  • Person who have intake history of food or drug which can affect drug absorption, drug distribution, drug metabolism, and drug excretion and bowel activity
  • Volunteer have a history of donation of whole blood donation, apheresis, transfusion
  • Volunteer a heavy drinker(30g/day), smoker(10 cigarettes/day), heavy caffeine consumer(400mg/day)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    CJ-12420 200 mg + Clarithromycin 500mg

    CJ-12420 200mg QD for 5 days + Clarithromycin 500mg BID for 5 days

    Drug: CJ-12420 200mg · Drug: Clarithromycin 500mg

  • Active comparator
    CJ-12420 200mg

    CJ-12420 200mg QD for 5 days

    Drug: CJ-12420 200mg + Clarithromycin 500mg · Drug: Clarithromycin 500mg

  • Active comparator
    Clarithromycin 500mg

    Clarithromycin 500mg BID for 5 days

    Drug: CJ-12420 200mg + Clarithromycin 500mg · Drug: CJ-12420 200mg

Interventions

  • DrugCJ-12420 200mg + Clarithromycin 500mg

    Drug page: Tegoprazan

    To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.

    Also known as: CJ-12420 200mg for 5 days + Clarithromycin 500mg for 5 days

  • To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.

    Also known as: CJ-12420 200mg for 5 days

  • To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.

    Also known as: Clarithromycin 500mg for 5 days

06

What researchers measure

Primary outcomes

  1. The effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin

    Cmax, Cmin, Tmax, AUC(tau), CL/F, T1/2

    Time frame: Blood sampling during 12 or 24hrs after administration

Secondary outcomes

  1. The safety of the coadministration of multiple dose of CJ-12420 and clarithromycin in healthy subjects

    Safety and tolerability parameters will include laboratory (haematology, clinical chemistry, urinalysis, 12-lead ECG) values at Screening, Day-1 and Day 6 at each period and Follow-up.

    Time frame: 6 days after last visit

07

Study locations

1 site
  • Inje university college of medicine Busan Paik Hospital
    Busan, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Jan 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2014
First posted
Feb 3, 2014
Start
Oct 2013
Primary completionActual
Jan 2014
CompletionActual
Nov 2014
Last update
Dec 15, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02052336
Responsible party
Sponsor
First posted
Feb 3, 2014
Start date
Oct 2013
Primary completion
Jan 2014
Completion
Nov 2014
Last update
Dec 15, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tegoprazan · Clarithromycin

Start the discussion